Vous avez cherché: neurodegenerative (Anglais - Maltais)

combating alzheimer's and neurodegenerative diseases.
il-ġlieda kontra l-alzheimer u l-mard newro-deġenerattiv.

joint programming initiative on combating neurodegenerative diseases
inizjattivi ta' programmar konġunt dwar il-ġlieda kontra l-mard newrodeġenerattiv

combating neurodegenerative diseases, in particular alzheimer's
niĠĠieldu kontra l-mard newrodeĠenerattiv, b'mod partikolari l-marda ta' alzheimer

combating alzheimer's and neurodegenerative diseases - council conclusions
il-ġlieda kontra l-alzheimer u l-mard newro-deġenerattiv - konklużjonijiet tal-kunsill

neurodegenerative diseases are recognised by the ms as a major societal challenge.
il-mard newrodeġenerattiv huwa rikonoxxut mill-istati membri bħala sfida kbira tas-soċjetà.

commission steps up action on alzheimer's disease and other neurodegenerative conditions
il-kummissjoni żżid l-azzjoni fil-qasam tal-marda ta' alzheimer u kundizzjonijiet newrodeġenerattivi oħra

alzheimer's disease and other dementias are part of the broader neurodegenerative diseases.
il-marda ta' alzheimer u dimenzji oħra huma parti minn grupp ħafna usa' ta' mard deġenerattiv.

dementias are a group of neurodegenerative diseases and are not just a part of the normal ageing process.
id-dimenzji huma grupp ta’ mard newrodeġenerattiv u mhumiex biss parti mill-proċess normali tat-tixjiħ.

the first joint programming initiative to coordinate research on alzheimer’s and other neurodegenerative diseases
l-ewwel inizjattiva ta' programmazzjoni konġunta sabiex tiġi kkoordinata r-riċerka dwar il-marda ta' alzheimer u mard deġenerattiv ieħor

a pilot joint programming initiative started on 'neurodegenerative diseases including alzheimer's';
bdiet inizjattiva pilota għall-ipprogrammar konġunt dwar 'mard newrodeġenerattiv inkluż l-alzheimer's';

on measures to combat neurodegenerative diseases, in particular alzheimer's, through joint programming of research activities
dwar miżuri għall-ġlieda kontra l-mard newrodeġenerattiv, b'mod partikolari l-marda ta' alzheimer, permezz ta' programmazzjoni konġunta tal-attivitajiet tar-riċerka

a pet scan with florbetaben (18f) should be requested by clinicians experienced in the clinical management of neurodegenerative disorders.
pet skenn bi florbetaben (18f) għandha tkun mitluba minn tobba b’esperjenza fil-ġestjoni klinika ta’ disturbi newrodeġenerattivi.

niemann-pick type c disease is a very rare, invariably progressive and eventually fatal neurodegenerative disorder characterised by impaired intracellular lipid trafficking.
il-marda ta’ niemann-pick ta’ tip Ċ hija disturb newrodeġenerattiv rari ħafna, progressiv b’mod kostanti u eventwalment fatali, ikkaratterizzat minn traffikar indebolit tal-lipidi fiċ-ċelluli.

23 countries have engaged in the pilot joint programming initiative (jpi) on neurodegenerative diseases, including alzheimer's.
23 pajjiż taw l-impenn tagħhom fil-proġett pilota inizjattiva ta' programmar konġunt (joint programming initiative - jpi) tar-riċerka dwar il-mard newrodeġenerattiv, inkluża l-marda tal-alzheimer’s.

(f) network centres dedicated to research on neurodegenerative diseases in areas such as clinical trials, standardisation of diagnostic criteria and diagnostic instruments.
(f) ċentri ta' netwerk jiġu ddedikati għar-riċerka dwar il-mard newrodeġenerattiv f'oqsma bħalma huma l-provi kliniċi, l-istandardizzazzjoni tal-kriterji dijanjostiċi u l-istrumenti dijanjostiċi.

there is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at nmda-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.
aktar evidenza qed tindika li l-funzjoni ħażina ta’ newrotrasmissjoni glutamaterġika, b’mod partikolari fir-riċetturi-nmda, jagħtu kontribut kemm għall-espressjoni tas-sintomi kif ukoll għall- avvanz ta’ dimenzja newrodiġenerattiva.

a positive scan on its own, however, is not sufficient to make a diagnosis in patients with memory problems, as plaque deposition may be seen in patients with different types of neurodegenerative dementias as well as in elderly people with no symptoms.
immaġini pożittiva weħidha, madankollu, mhijiex biżżejjed biex issir dijanjosi f’pazjenti bi problemi bil-memorja, peress li depożiti ta’ plakka jistgħu jidhru fuq pazjenti b’tipi differenti ta’ dimenzji newrodeġenerattivi kif ukoll fuq anzjani mingħajr ebda sintomi.

first steps are being taken to promote cooperation in public research efforts targeting key priorities related to neurodegenerative diseases, in particular alzheimer’s, at european level through a joint programming approach25.
fil-livell ewropew qed jittieħdu l-ewwel passi għall-promozzjoni tal-kooperazzjoni fl-isforzi tar-riċerka pubblika li timmira l-prijoritajiet ewlenin marbuta mal-mard newrodeġenerattiv, partikolarment il-marda ta’ azheimer, permezz ta’ programmazzjoni konġunta25.

the agency will fully embrace its responsibility to assess four classes of medicines for which authorisation must now be sought through the centralised procedure: those for hiv/ aids, cancer, diabetes and neurodegenerative disorder.
l- aġenzija ser tħaddan b' mod sħiħ ir- responsabilità tagħha biex tivvaluta erba 'klassijiet ta' mediċini li għalihom issa trid tinkiseb l- awtorizzazzjoni permezz tal- proċedura ċentralizzata: dawk għall- hiv/ aids, il- kanċer, id- dijabete u l- mard newrodeġenerattiv.

3.3.1 the suspected risks include: disorders of the neuroendocrine system (hormones, melatonin), neurodegenerative disorders (parkinson's, alzheimer's, sclerosis), effects on human and/or animal reproduction and development (risk of miscarriage, deformities) and increased risk of cancer (brain tumours, childhood leukaemia).
3.3.1 fost ir-riskji ssuspettati nsibu: problemi fis-sistema newroendokrinali (ormoni, melatonina), problemi newrodeġenerattivi (marda ta’ parkinson, marda tal-alzheimer, sklerosi), effetti fuq ir-riproduzzjoni u l-iżvilupp tal-bnedmin u/jew tal-annimali (riskji ta’ korriment, malformazzjonijiet) u riskji akbar ta’ kanċer (tumuri fil-moħħ, lewkimja fit-tfal).